Windward Bio Group AG (WWB) is a Basel, Switzerland-based clinical-stage biotechnology company developing ultra-long-acting antibody medicines for serious respiratory and dermatologic diseases, including asthma, COPD and atopic dermatitis. It has no approved products and no revenue. In the latest session the stock closed at $22.64, down $3.12, or 12.11%, from the previous close of $25.76, confirming a decisive downward move that extended a three-session slide from $30.04. No verified company-specific catalyst was found. The decline followed the completion of the company's initial public offering and its private placement with Sanofi (SNY), and reflects the unwinding of the outsized premium the shares commanded in their first days of trading.
Windward priced its offering at $17.00 per share and began trading on the Nasdaq on November 13, closing its first session at $28.50 — 67.65% above the offer price — after printing an intraday high of $33.99. The stock added another 5.40% on November 16 to $30.04, then turned sharply lower, losing 14.25% in the following session and 12.11% in the latest one. Shares now sit roughly 33% above the IPO price and about 33% below their high.
That pattern is a textbook first-week round trip. New issues with a narrow public float and no earnings history are dominated in early trading by IPO allocators, short-term momentum funds and retail buyers, and the bid thins quickly once the initial scramble ends. The absence of any sell-side price target — underwriters cannot publish research during the quiet period — removes a key support for valuation and leaves the stock trading purely on order flow.
On November 16 the company closed its IPO of 11,838,234 common shares, including full exercise of the underwriters' option to purchase an additional 1,544,117 shares, at $17.00 per share, alongside a concurrent private placement of 1,532,691 common shares and pre-funded warrants for 1,408,485 shares to Sanofi Foreign Participations B.V. Gross proceeds from the IPO and placement totaled approximately $251.2 million.
Full exercise of the greenshoe confirmed strong institutional demand at the offer price, but it also means more stock is now in the market than the base deal implied. More importantly, Sanofi's position was struck at $17.00, leaving that holder with a sizeable paper gain even after the pullback. Buyers are therefore trading against a known, in-the-money block that can be monetized, a classic overhang for freshly listed biotechs.
Nothing in the news flow justifies a fundamental re-rating. The only material corporate disclosure was the November 16 offering-closing release; there have been no clinical updates, regulatory actions, financing announcements or management changes since. Rating changes are not possible while the quiet period runs to December 23.
What is left is valuation. Windward trades at roughly five times book value and derives none of its market capitalization from revenue, only from the optionality of two in-licensed antibody programs. With the nearest meaningful data still quarters away, the stock has little to defend an elevated post-IPO multiple once momentum money exits.
Volume of about 518,000 shares came in below the roughly 760,000 three-month average, indicating an orderly retreat rather than panic liquidation, though turnover was still heavy relative to the 10.29 million shares sold in the offering. The session's range of $21.01 to $29.95 — a swing of about 35% — underlines how thin the order book remains. The stock broke below both its debut-day close of $28.50 and its November 16 close of $30.04 and is now testing the lower half of its four-session range, holding above the $18.35 first-day low and comfortably above the $17.00 offer price.
No sector-wide trigger was identified: the move was idiosyncratic to this new issue rather than a read-across from large-cap biotechnology or the broader indices.
The score runs from 0, meaning no meaningful news and a price move that is normal for the stock, to 100, meaning transformative news and an extreme, rare move. Windward Bio Group scores 14 out of 100.
The verified news was routine: completion of an already-announced IPO and placement, with no change to the clinical or financial outlook, so catalyst strength was minimal relative to the company's roughly $1.3 billion market value. The price move was also unremarkable by this stock's own standards. The 12.11% decline was only about 1.2 times the 9.8% average absolute move of the two preceding sessions, and smaller than the 14.25% drop on November 17; two of the three prior sessions produced equal or larger moves. Weak news plus a typical move yields a low score.
The calendar is dominated by coverage rather than data. The quiet period expires on December 23, after which Jefferies, TD Cowen, Piper Sandler and UBS — the joint book-running managers — are expected to initiate research, a potential two-way catalyst. The company has not yet guided to a first earnings date as a public issuer.
The clinical path is where the equity story lives: top-line Phase 2 asthma data from POLARIS-1 in the first half of 2027, Phase 2 COPD results from SIRIUS in the second half of 2027, Phase 3 asthma data in the first half of 2029, and Phase 2b COPD and Phase 2 atopic dermatitis studies of WIN027 beginning enrollment in the first half of 2027. Management expects existing cash plus offering proceeds to fund operations into the first half of 2029.
Risks include continued cash burn, the possibility of future equity issuance, intense competition in the TSLP space, execution risk on in-licensed assets, and the volatility that comes with a small float. Investors should expect wide daily ranges to persist.
Tickeron's Trending AI Robots page curates the platform's strongest performing automated strategies at any given moment. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, and only those delivering the best results in current market conditions make this featured list. Bots differ widely by strategy logic, timeframe, performance metrics and the symbols they trade, so the roster rotates as conditions change. Reviewing the trending lineup is a practical way to see which approaches are working now and to compare them with your own process.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology